AstraZeneca and BenevolentAI announce second major collaboration milestone

15 December 2021

UK-based artificial intelligence (AI) company BenevolentAI today said that AstraZeneca (LSE: AZN) has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's platform, to its drug development portfolio.

This is the second novel target from the collaboration that has been identified, validated, and selected for AstraZeneca's portfolio. In January this year, the Anglo-Swedish pharma major selected a novel chronic kidney disease (CKD) target.

BenevolentAI's strategic collaboration with AstraZeneca began in 2019, and currently focuses on discovering potential new treatments for IPF and chronic kidney disease (CKD). The innovative collaboration structure sees scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform - an AI-driven drug discovery platform - and biomedical knowledge graph with AstraZeneca's scientific expertise and rich datasets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK